3 completed, 1 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow GEN-1: new trials by email Literature Review of GEN-1 trials Research Report on GEN-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer IMNN-001 - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Imunon | 18 | 2015-09-01 | 2024-10-02 |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 16 | 2012-07-09 | 2019-03-12 |
| Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms | Phase 1 | Completed | EGEN, Inc. | 13 | 2007-04-01 | 2013-03-26 |
| Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer EGEN-001 (phIL-12-005/PPC) - Ovarian Neoplasms | Phase 1 | Terminated | EGEN, Inc. | 18 | 2005-08-01 | 2013-02-28 |
Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Carcinoma, Ovarian Epithelial (1)
EGEN, Inc. (2) · Gynecologic Oncology Group (1) · Imunon (1)
United States (4)
Premal H Thaker (1) · Premal Thaker, M.D. (1) · Ronald Alvarez, MD (1) · Ronald D. Alvarez, MD (1)
U10CA027469 (1), U10CA180868 (1)